Field of the Invention
The present invention relates to an apparatus and method for providing negative pressure at a wound site. In particular, but not exclusively, the present invention relates to an apparatus including a source of negative pressure which acts as a negative pressure reservoir to continually or repeatedly “top up” an applied negative pressure so that negative pressure applied at a wound site can be maintained within desired limits for a relatively long period of time.
Description of the Related Art
Devices for the generation of negative pressure at the surface of skin have been used for many hundreds of years to treat animal and human bodies. For example the cupping technique (which relates to the positioning of a mouth of a rigid vessel containing hot air) is a well known technique. Spring powered syringes and suction cups are other mechanical techniques which have been used in the past for generating a vacuum on tissue. In common with cupping such techniques have, in the past, suffered from a very limited longevity of the therapy which can be applied. That is to say the duration of the negative pressure which can be maintained over a site of application has been limited.
To enable a more prolonged application of controlled negative pressure, powered systems, which include a vacuum generation source such as a pump of some type have been developed and many examples of such systems are used today for the management of wounds. However, many of these systems are not convenient for discreet use by a patient as they are large, can be heavy and are often noisy. Furthermore the production costs associated with such systems are substantial due largely to the cost of materials and complexity of assembly.
Attempts have been made to produce a mechanical device able to apply negative pressure to a wound site. It will be appreciated that such a mechanical device, due to its simplicity of design, would be expected to reduce material costs and assembly costs. For example, US 2008/200905 discloses a hand-pump system for the application of negative pressure at a tissue site. However, the system described does not enable prolonged convenient application of negative pressure at the wound site and in fact requires re-evacuation relatively often. This is a serious deficiency particularly as many such systems should ideally be useable overnight.
It is an aim of the present invention to at least partly mitigate the above-mentioned problems.
It is an aim of certain embodiments of the present invention to provide an apparatus which can be manufactured and assembled in a convenient and thus cost effective manner yet which can provide a negative pressure at a wound site within desired pressure limits over a period of time prolonged with respect to prior art techniques.
It is an aim of certain embodiments of the present invention to provide one, two or more negative pressure reservoirs or a series of negative pressure reservoirs which act as backups for the negative pressure generated at a wound site.
It is an aim of certain embodiments of the present invention to provide a system for applying negative pressure at a wound site which can remain active for at least ten hours without user interference being needed to cause re-evacuation. This enables a user to sleep undisturbed.
According to a first aspect of the present invention there is provided apparatus for providing negative pressure at a wound site, comprising:
According to a second aspect of the present invention there is provided a method of providing negative pressure at a wound site, comprising the steps of:
Certain embodiments of the present invention enable the prolonged application of reduced pressure at a wound site in a convenient and cost effective manner. For example a reduced pressure device can create a safe reduced pressure at the site of application (i.e. no greater than 200 mmHg below ambient atmospheric pressure) that is connected by at least one valve to at least one further negative pressure reservoir. By selectively connecting a high vacuum (i.e. greater than 200 mmHg below ambient atmospheric pressure) stored in the reservoir to the wound site via a pressure regulating valve the duration of therapy can be prolonged and also a desired negative pressure level at the wound site can be set and maintained.
Certain embodiments of the present invention utilise multiple negative pressure reservoirs each of which is independently connected via a control valve and conduit to a contact chamber formed at a wound site. This has the advantage that the user is able to select the appropriate pressure for the wound. Multiple valves set at different pressures e.g. 50 mmHg, 75 mmHg and 100 mmHg can be attached to a single reservoir to allow the user to select a pressure by isolation or lock down of the 2 valves not in use with simple shut off valves. Also malfunction of an individual control valve does not disable the whole system.
Certain embodiments of the present invention utilise a series of negative pressure reservoirs cascading one into another and eventually a contact chamber and separated by respective control valves. This has the advantage that a safety mechanism is built into the device such that a single failure (e.g debris in the valve) of a valve does not result in the wound being exposed to excessive possibly dangerous pressures. Aptly the largest reservoir is the one set at the most negative pressure in order to get maximum longevity of therapy for size of product. Also the mechanical properties of each reservoir can be tailored to provide optimal vacuum performance over a specified negative pressure range.
Embodiments of the present invention will now be described hereinafter, by way of example only, with reference to the accompanying drawings in which:
In the drawings like reference numerals refer to like parts.
As illustrated in
An aspiration conduit 15 is located through a pinched section 16 of the drape 11 so as to provide a sealed tubular conduit under the drape into the wound site. The wound packer and aspiration conduit thus cooperate to resist crushing under the levels of vacuum created at the wound site and permit transfer of wound exudates across the wound area to the aspiration conduit sealed to the flexible cover drape which extends over the wound.
The aspiration conduit may be a plain flexible tube, for example, having a single lumen therethrough and made from a plastics material compatible with raw tissue. However, the aspiration conduit may alternatively have a plurality of lumens therethrough to achieve specific objectives. A portion of the tube sited within the wound chamber may aptly have a structure to enable continued aspiration and evacuation of wound exudate without becoming constricted or blocked even at the high levels of negative pressure envisaged.
It is envisaged that the negative pressure range for the apparatus embodying the present invention may be between about −50 mmHg and −200 mmHg (note that these pressures are relative to normal ambient atmospheric pressure thus, −200 mmHg would be around 560 mmHg in practical terms). Aptly, the pressure range may be between about −75 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also aptly a pressure range of below −75 mmHg could be used. Alternatively a pressure range of over −100 mmHg could be used or over −150 mmHg. Aptly the pressure of the wound chamber is between −125 mmHg and −20 mmHg. It will thus be appreciated that negative pressure is taken to mean a pressure that is less than ambient atmospheric pressure.
The aspiration conduit 15 thus has an end proximate to the dressing and wound site. At a distal end remote from the dressing and wound site the aspiration conduit is secured to a valve 17. This in turn is connected via a conduit to a negative pressure reservoir 18 and further control valve 19. A fluid communication path is thus established between the valve 19, negative pressure reservoir 18, reservoir valve 17 and wound chamber 14.
Whilst embodiments of the present invention will be described hereinafter by way of reference to a wound chamber 14 defined at a wound site under a drape it will be understood that certain embodiments of the present invention can be utilised to maintain a negative pressure in a wound chamber which is a rigid structure or partly rigid structure such as a cup device placed over a wound site.
It will be understood that rather than containing many resilient beads one or more blocks of resilient material such as foam could be utilised within the reservoir body 20 to prevent collapse. It is advantageous that as a negative pressure established in the negative pressure reservoir 18 diminishes the filler expands so as to increase the volume in the reservoir. Aptly the filler material is selected so that expansion occurs over the whole range of pressures experienced in the negative pressure reservoir. This can be achieved by using a single resilient material having a characteristic which makes the filler expand over a broad pressure range or by providing filler materials of different materials. For example some of the beads 24 may be manufactured of a material which expands over a particular pressure range whilst other beads are manufactured of a different material which expands over a different pressure range.
Absorber material is aptly held in the negative pressure reservoir. The absorber material can be any type of material able to absorb wound exudate or other liquid being drawn from the wound site into the reservoir 18 through the aspiration tube 15 and reservoir valve 17. The absorber 25 is aptly an absorber gel such as ISOLYSEL™. The absorbent can be separated from the filler material (as shown) or be integral therewith. An added advantage of using such a gel matrix is that when exudate is stored excessive movement of the liquid is prevented such as slopping of the liquid. This also minimises bacterial growth and minimises odours.
It will be appreciated that the various tubes are connected to the fluid reservoir via a fluid tight connection which might be either a tight friction fit or a fitting which requires some securing mechanism such as a jubilee clip or the like. Further examples of possible methods of connection may be adhesive, welding or use of a snap together connector for example as manufactured by Colder Products.
Returning to
Over time it is inherent that small leakage paths are formed between the drape 11 and surrounding tissue 13. Also it is possible that leakage paths are created around the pinched region 16 in the drape. As a result the negative pressure applied at the wound site degrades, that is to say becomes less negative over time. The negative pressure reservoir valve 17 is selected to open and close automatically responsive to a pressure difference between the pressure in the aspiration tube 15 and wound site and the tubing and negative pressure reservoir 18. As the negative pressure in the wound site increases the reservoir valve 17 opens providing a fluid communication path between the wound chamber and the negative pressure reservoir. The result is that the wound chamber pressure becomes more negative whilst the negativity of the negative pressure in the reservoir 18 reduces. Over time the valve 17 opens and closes continually or repeatedly so as to deplete the source of negative pressure in the reservoir. During this period of time the negative pressure applied at the wound site is maintained as much as possible within desired negative pressure ranges.
As a result the prolonged application of a reduced pressure is enabled at the tissue site in a convenient and cost effective manner. A safe reduced pressure of, for example, no greater than 200 mmHg below ambient atmospheric pressure is created and applied at the site of application. The valves connecting the reservoir to the wound site are fail safe and will only open when there is a loss of vacuum within the wound chamber. Furthermore the valves are selected so as to close when the pressure at the wound site reaches a desired target specified by the pressure valve manufacturer. Thus by connecting a high vacuum reservoir to a wound site via a pressure regulating valve the duration therapy can be prolonged in contrast to the prior art.
An example of a vacuum pressure regulation valve of a type suitable according to certain embodiments of the present invention is the VRD-ANB-CD vacuum regulator as supplied by Beswick Engineering™. It will be appreciated that other fluid flow control valves used to turn on and off a flow of fluid can be utilised according to certain embodiments of the present invention.
Series connection of negative pressure reservoirs is useful for the controlled delivery of vacuum to the wound chamber. Pressure surges can be avoided in the event of single valve failure.
It will be appreciated that a combination of series and parallel connected negative pressure reservoirs can be utilised according to certain embodiments of the present invention. Also that one, two or more negative pressure reservoirs can be utilised.
Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
Number | Date | Country | Kind |
---|---|---|---|
0900423.5 | Jan 2009 | GB | national |
This application is a continuation of U.S. patent application Ser. No. 13/144,264, filed Jul. 12, 2011, now U.S. Pat. No. 9,180,231, which is a U.S. National Phase of PCT International Application No. PCT/GB2010/050020, filed on Jan. 8, 2010, designating the United States and published on Jul. 15, 2010 as WO 2010/079359, which claims priority to Great Britain Patent Application No. 0900423.5, filed on Jan. 12, 2009. The disclosure of all prior applications are incorporated by reference herein in their entireties and should be considered part of this application.
Number | Name | Date | Kind |
---|---|---|---|
3572340 | Lloyd et al. | Mar 1971 | A |
3721239 | Myers | Mar 1973 | A |
3863664 | Holbrook et al. | Feb 1975 | A |
3983872 | Nehring | Oct 1976 | A |
3991763 | Genese | Nov 1976 | A |
4388922 | Telang | Jun 1983 | A |
4392860 | Huck et al. | Jul 1983 | A |
4525166 | Leclerc | Jun 1985 | A |
4735606 | Davison | Apr 1988 | A |
4969880 | Zamierowski | Nov 1990 | A |
5549584 | Gross | Aug 1996 | A |
5549585 | Maher et al. | Aug 1996 | A |
5738656 | Wagner | Apr 1998 | A |
5876387 | Killian et al. | Mar 1999 | A |
6371947 | Gibertoni | Apr 2002 | B1 |
6824533 | Risk, Jr. et al. | Nov 2004 | B2 |
7700819 | Ambrosio et al. | Apr 2010 | B2 |
8007257 | Heaton et al. | Aug 2011 | B2 |
8062272 | Weston | Nov 2011 | B2 |
8157775 | Bobroff et al. | Apr 2012 | B2 |
8162909 | Blott et al. | Apr 2012 | B2 |
8273368 | Ambrosio et al. | Sep 2012 | B2 |
8323264 | Weston et al. | Dec 2012 | B2 |
8366690 | Locke | Feb 2013 | B2 |
8382731 | Johannison | Feb 2013 | B2 |
8398614 | Blott et al. | Mar 2013 | B2 |
8679081 | Heagle et al. | Mar 2014 | B2 |
8715256 | Greener | May 2014 | B2 |
8808259 | Walton et al. | Aug 2014 | B2 |
9180231 | Greener | Nov 2015 | B2 |
9205183 | Hartwell et al. | Dec 2015 | B2 |
20040054338 | Bybordi et al. | Mar 2004 | A1 |
20070185463 | Mulligan | Aug 2007 | A1 |
20070225663 | Watt et al. | Sep 2007 | A1 |
20070265585 | Joshi | Nov 2007 | A1 |
20080108977 | Heaton et al. | May 2008 | A1 |
20080200905 | Heaton et al. | Aug 2008 | A1 |
20090030383 | Larsen et al. | Jan 2009 | A1 |
20090126103 | Dietrich et al. | May 2009 | A1 |
20100042021 | Hu et al. | Feb 2010 | A1 |
20100125259 | Olson | May 2010 | A1 |
20100268177 | Hall et al. | Oct 2010 | A1 |
20110009838 | Greener | Jan 2011 | A1 |
20110105963 | Hu et al. | May 2011 | A1 |
20110125113 | Adahan | May 2011 | A1 |
20120109085 | McNeil | May 2012 | A1 |
20130018338 | Weston et al. | Jan 2013 | A1 |
20130253453 | Olson | Sep 2013 | A1 |
20130296816 | Greener | Nov 2013 | A1 |
20190321524 | Greener | Oct 2019 | A1 |
Number | Date | Country |
---|---|---|
15716852 | Jan 2005 | CN |
1 163 907 | Oct 1958 | FR |
WO 9611031 | Apr 1996 | WO |
WO 2003018098 | Mar 2003 | WO |
WO 2009002260 | Dec 2008 | WO |
WO 2009071928 | Jun 2009 | WO |
WO 2009102021 | Aug 2009 | WO |
WO 2009103031 | Aug 2009 | WO |
WO 2009126103 | Oct 2009 | WO |
Entry |
---|
International Preliminary Report on Patentability, re PCT Application No. PCT/GB2010/050020, dated Jul. 12, 2011. |
International Search Report, re PCT Application No. PCT/GB2010/050020, dated Apr. 29, 2010. |
“Negative Pressure Wound Therapy”, BlueSky Medical, Product Catalog 2006 (LBL-00224-01-AD), in 8 pages. |
Notice of Opposition — Statement of Facts and Evidence, re European Patent No. Ep 2 385 849, dated Jun. 5, 2019, in 11 pages. |
Reply of the Patent Proprietor to the Notice(s) of Opposition, re the Opposition of European Patent No. Ep 2 385 849, dated Oct. 25, 2019, in 25 pages. |
Annex to the Communication—Provisional Non-Binding Opinion, re the Opposition of European Patent No. EP 2 385 849, dated Jan. 23, 2020, in 4 pages. |
Number | Date | Country | |
---|---|---|---|
20160095966 A1 | Apr 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13144264 | US | |
Child | 14881022 | US |